BioSpace News Archive

Henry Schein, Inc., the world’s largest provider of health care solutions to office-based dental and medical practitioners, reported financial results for the first quarter ended April 1, 2023.

Perrigo Company plc (NYSE: PRGO) (“Perrigo” or the “Company”), a leading provider of Consumer Self-Care Products, today announced financial results from continuing operations for the first quarter ended April 1, 2023.

Eagle Pharmaceuticals, Inc. announced financial results for the three months ended March 31, 2023.

Waters Corporation announced its financial results for the first quarter of 2023.

Noema Pharma, a clinical-stage biotech company targeting debilitating central nervous system disorders, announced that senior members of its Management Team will present at BioEquity Europe taking place May 14-16, 2023, in Dublin, Ireland.

TELA Bio, Inc., a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s own anatomy, will sponsor a Women in Surgery Dinner on May 10, 2023, at the International Hernia Collaboration Conference in Rio de Janeiro, Brazil.

ALX Oncology Holdings Inc. announced the initiation of a Phase 2 investigator-sponsored trial of evorpacept, a next generation CD47 blocker, in combination with liposomal doxorubicin and KEYTRUDA®, Merck’s anti-PD-1 therapy, in patients with recurrent platinum-resistant ovarian cancer at the UPMC Hillman Cancer Center.

Mersana Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates targeting cancers in areas of high unmet medical need, provided a business update and reported financial results for the first quarter ended March 31, 2023.

Axogen, Inc., a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, reported financial results and business highlights for the first quarter ended March 31, 2023.

Voyager Therapeutics, Inc., a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, reported first quarter 2023 financial and operating results.